AstraZeneca·Healthcare / Pharmaceuticals·Cambridge, United Kingdom·Founded 1913·Last verified 31 May 2026
52
out of 100
Making progressPending ReviewMixed evidence· 12 src

AstraZeneca has cut operational emissions 77.5% since 2015 and locked in science-based net-zero targets, but absolute supply chain emissions are rising 18.6% from baseline. Operations excel; supply chain and delivery risk on Scope 3 are the dominant weaknesses. Trade association memberships undermine climate advocacy clarity.

The calculation

Every score shows its working.

Same formula for every company. No curve. No private weighting.

SINK = (0.3 × Base + 0.7 × Performance) × Scale
Industry base impact
Healthcare / Pharmaceuticals sector ceiling.
45 / 100
Performance score
Sum of the 10 rubric questions, scored 0–10 each.
72 / 100
Raw score
Weighted average before scale penalty.
(0.3 × 45) + (0.7 × 72) = 63.9
Scale penalty
Multiplier based on absolute emissions volume — physics-first.
× 0.82
Final score
Rounded. Making progress.
52 / 100
The ten questions

Where AstraZeneca is strong, and where it isn't.

Strongest on Carbon Footprint — Operations and Energy Source (9/10, 9/10). Weakest on Emissions Trajectory and Resource Use & Waste (4/10, 6/10).

Where the evidence comes from

Every document used, listed.

12 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.

[1]Self-reported
Sustainability Data Annex 2024
2025
Q1Q2Q3Q6Q7Q8
View →
[2]Self-reported
Greenhouse Gas Methodologies 2024
2024
Q1Q2
View →
[3]Third-party verified
SBTi Supplier Engagement Case Study: AstraZeneca
Unknown
Q2Q8
View →
[4]Self-reported
Renewable Energy Initiatives
Ongoing
Q4
View →
[5]Third-party verified
24/7 Carbon-Free Electricity Coalition — The Climate Group
Unknown
Q4
View →
[6]Self-reported
AstraZeneca TNFD Report 2024
2025
Q5
View →
[7]Self-reported
AstraZeneca Biodiversity Statement
Unknown
Q5
View →
[8]Self-reported
Nature & Biodiversity Hub
Ongoing
Q5Q6
View →
[9]Self-reported
Data Index 2024
2024
Q9
View →
[10]Self-reported
Sustainability Resources Hub
Ongoing
Q9
View →
[11]Third-party verified
SBTi Net-Zero Case Study: AstraZeneca
Unknown
Q3Q8
View →
[12]Third-party verified
InfluenceMap Lobbymap — AstraZeneca
Unknown
Q10
View →

If you believe a source has been misread or a newer version exists, submit a challenge.

AstraZeneca in context

AstraZeneca is the highest-scoring healthcare / pharmaceuticals company we've rated.

Among the 11 major healthcare / pharmaceuticals brands we've scored, AstraZeneca sits 1st of 11.

1/11
AstraZeneca's rank
46
Industry average
39
Industry low
52
Industry high
How this score has moved

AstraZeneca's score over time.

today

Score history begins 4 April 2026.

As AstraZeneca's score updates, the trajectory will appear here.

We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.

What's being contested

This score is not currently being contested.

Every challenge is published. We'd rather be corrected than wrong — that's the whole point.

No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.

About AstraZeneca

AstraZeneca is a British-Swedish pharmaceutical company headquartered in Cambridge, UK, founded in 1913. With 70,600 employees and $24.4B FY2019 revenue, it ranks among the world's largest research-driven drugmakers, operating across oncology, cardiovascular, and respiratory therapy segments.

Founded
1913
Headquarters
Cambridge, United Kingdom
Employees
~94,300
Annual revenue
~$54.1B
Company website ↗
Track AstraZeneca

We'll let you know when the score moves.

Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.

THE SUNDAY RUNDOWN

Which companies moved this week, and why.

One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.

No spam. Unsubscribe in one click.

HOW SINK STAYS INDEPENDENT

Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.